Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era

Santosha A. Vardhana, Craig S. Sauter, Matthew J. Matasar, Andrew D. Zelenetz, Natasha Galasso, Kaitlin M. Woo, Zhigang Zhang, Craig Moskowitz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, its role in those patients achieving less than a complete response to first-line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant-eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high-dose therapy and ASCT to patients achieving chemosensitive remission. The estimated 3-year overall and progression-free survival for all patients was 38% and 29%, respectively, and 65% and 60% respectively for patients proceeding to stem cell transplant. Long-term remission was achieved in 45% of patients achieving a partial response (PR) to initial induction therapy and <20% of patients with stable or progression of disease following initial therapy. These results suggest that salvage chemotherapy with the intent of subsequent high-dose therapy and ASCT remains a feasible strategy in certain patients with primary refractory DLBCL, particularly for those achieving a PR to frontline therapy. The primary barrier to curative therapy in patients with primary refractory disease is resistance to salvage therapy, and future studies should be aimed towards increasing the response rate in this population.

Original languageEnglish (US)
Pages (from-to)591-599
Number of pages9
JournalBritish Journal of Haematology
Volume176
Issue number4
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Transplants
Drug Therapy
Stem Cells
Salvage Therapy
Therapeutics
Rituximab
Disease Resistance
Standard of Care
Disease-Free Survival
Disease Progression

Keywords

  • DLBCL
  • lymphoma
  • refractory
  • rituximab
  • transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. / Vardhana, Santosha A.; Sauter, Craig S.; Matasar, Matthew J.; Zelenetz, Andrew D.; Galasso, Natasha; Woo, Kaitlin M.; Zhang, Zhigang; Moskowitz, Craig.

In: British Journal of Haematology, Vol. 176, No. 4, 01.02.2017, p. 591-599.

Research output: Contribution to journalArticle

Vardhana, Santosha A. ; Sauter, Craig S. ; Matasar, Matthew J. ; Zelenetz, Andrew D. ; Galasso, Natasha ; Woo, Kaitlin M. ; Zhang, Zhigang ; Moskowitz, Craig. / Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. In: British Journal of Haematology. 2017 ; Vol. 176, No. 4. pp. 591-599.
@article{05647f01bf964c2fbdc1381a70f5e077,
title = "Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era",
abstract = "Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, its role in those patients achieving less than a complete response to first-line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant-eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high-dose therapy and ASCT to patients achieving chemosensitive remission. The estimated 3-year overall and progression-free survival for all patients was 38{\%} and 29{\%}, respectively, and 65{\%} and 60{\%} respectively for patients proceeding to stem cell transplant. Long-term remission was achieved in 45{\%} of patients achieving a partial response (PR) to initial induction therapy and <20{\%} of patients with stable or progression of disease following initial therapy. These results suggest that salvage chemotherapy with the intent of subsequent high-dose therapy and ASCT remains a feasible strategy in certain patients with primary refractory DLBCL, particularly for those achieving a PR to frontline therapy. The primary barrier to curative therapy in patients with primary refractory disease is resistance to salvage therapy, and future studies should be aimed towards increasing the response rate in this population.",
keywords = "DLBCL, lymphoma, refractory, rituximab, transplant",
author = "Vardhana, {Santosha A.} and Sauter, {Craig S.} and Matasar, {Matthew J.} and Zelenetz, {Andrew D.} and Natasha Galasso and Woo, {Kaitlin M.} and Zhigang Zhang and Craig Moskowitz",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/bjh.14453",
language = "English (US)",
volume = "176",
pages = "591--599",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era

AU - Vardhana, Santosha A.

AU - Sauter, Craig S.

AU - Matasar, Matthew J.

AU - Zelenetz, Andrew D.

AU - Galasso, Natasha

AU - Woo, Kaitlin M.

AU - Zhang, Zhigang

AU - Moskowitz, Craig

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, its role in those patients achieving less than a complete response to first-line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant-eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high-dose therapy and ASCT to patients achieving chemosensitive remission. The estimated 3-year overall and progression-free survival for all patients was 38% and 29%, respectively, and 65% and 60% respectively for patients proceeding to stem cell transplant. Long-term remission was achieved in 45% of patients achieving a partial response (PR) to initial induction therapy and <20% of patients with stable or progression of disease following initial therapy. These results suggest that salvage chemotherapy with the intent of subsequent high-dose therapy and ASCT remains a feasible strategy in certain patients with primary refractory DLBCL, particularly for those achieving a PR to frontline therapy. The primary barrier to curative therapy in patients with primary refractory disease is resistance to salvage therapy, and future studies should be aimed towards increasing the response rate in this population.

AB - Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, its role in those patients achieving less than a complete response to first-line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant-eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high-dose therapy and ASCT to patients achieving chemosensitive remission. The estimated 3-year overall and progression-free survival for all patients was 38% and 29%, respectively, and 65% and 60% respectively for patients proceeding to stem cell transplant. Long-term remission was achieved in 45% of patients achieving a partial response (PR) to initial induction therapy and <20% of patients with stable or progression of disease following initial therapy. These results suggest that salvage chemotherapy with the intent of subsequent high-dose therapy and ASCT remains a feasible strategy in certain patients with primary refractory DLBCL, particularly for those achieving a PR to frontline therapy. The primary barrier to curative therapy in patients with primary refractory disease is resistance to salvage therapy, and future studies should be aimed towards increasing the response rate in this population.

KW - DLBCL

KW - lymphoma

KW - refractory

KW - rituximab

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=85006985291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006985291&partnerID=8YFLogxK

U2 - 10.1111/bjh.14453

DO - 10.1111/bjh.14453

M3 - Article

C2 - 27982423

AN - SCOPUS:85006985291

VL - 176

SP - 591

EP - 599

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -